Lung and head/neck cancers exhibit mutation-stabilized Nrf2 enhancing ROS tolerance [81], while breast cancer utilizes Ras/MAPK-dependent Nrf2 activation [82]. The gene discussed is NFE2L2; the disease is head and neck cancer.